Siga Technologies (SIGA) Non-Current Deffered Revenue (2011 - 2018)
Siga Technologies' (SIGA) quarterly Non-Current Deffered Revenue came in at $376.0 million in Q1 2018, little changed on a YoY basis from $376.2 million in Q1 2017, and little changed quarter-over-quarter from $377.6 million in Q4 2017.
Analysis
Siga Technologies (SIGA) Non-Current Deffered Revenue (2011 - 2018) Analysis & Trends
Siga Technologies (SIGA) has reported Non-Current Deffered Revenue for 8 consecutive years, with $376.0 million the latest figure, recorded in Q1 2018.
- For the quarter ending Q1 2018, Non-Current Deffered Revenue changed 0.05% year-over-year to $376.0 million; the trailing twelve-month figure through Mar 2018 stood at $376.0 million (changed 0.05% YoY), and the FY2017 full-year result was $377.6 million, up 2.76% from the prior year.
- Non-Current Deffered Revenue was little changed at $376.0 million in Q1 2018 per SIGA's latest filing, from $377.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $377.6 million in Q4 2017 and bottomed at $81799.0 in Q4 2014.
- Historically, Non-Current Deffered Revenue has averaged $268.5 million across 5 years, with a median of $271.9 million in 2016.
- The sharpest annual moves came in 2014 and 2015: Non-Current Deffered Revenue plunged 99.95% in 2014, then soared 311955.61% in 2015.
- Over 5 years, Non-Current Deffered Revenue stood at $81799.0 in 2014, then jumped by 311955.61% to $255.3 million in 2015, then jumped by 43.97% to $367.5 million in 2016, then climbed by 2.76% to $377.6 million in 2017, then slipped by 0.43% to $376.0 million in 2018.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $376.0 million, $377.6 million, and $377.4 million for Q1 2018, Q4 2017, and Q3 2017 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Siga Technologies | 220.19 Mn | 65.22 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2018 | 376.03 Mn |
| Dec 31, 2017 | 377.64 Mn |
| Sep 30, 2017 | 377.45 Mn |
| Jun 30, 2017 | 376.48 Mn |
| Mar 31, 2017 | 376.20 Mn |
| Dec 31, 2016 | 367.48 Mn |
| Sep 30, 2016 | 367.12 Mn |
| Jun 30, 2016 | 288.29 Mn |
| Mar 31, 2016 | 255.47 Mn |
| Dec 31, 2015 | 255.26 Mn |
| Sep 30, 2015 | 255.09 Mn |
| Jun 30, 2015 | 233.74 Mn |
| Mar 31, 2015 | 13.53 Mn |
| Dec 31, 2014 | 81,799.00 |
| Jun 30, 2014 | 188.08 Mn |
| Mar 31, 2014 | 187.78 Mn |
| Dec 31, 2013 | 162.22 Mn |
| Sep 30, 2013 | 162.06 Mn |
| Jun 30, 2013 | 119.07 Mn |
| Mar 31, 2013 | 83.51 Mn |